Pharnext to Present at 2017 BIO CEO & Investor Conference
Pharnext SA (Paris:ALPHA) (FR00111911287 - ALPHA), a French biopharmaceutical company developing an advanced portfolio of products in the field of neurodegenerative diseases, announced today that company management will present a corporate overview at the 2017 BIO CEO & Investor Conference.
The presentation will take place as follows:
- Date : Monday, February 13th , 2017
- Time: 10:00 am ET (4:00 pm CET)
- Venue : The Waldorf Astoria in New York, New York.
If you are interested in meeting the Pharnext management team during this event, please send an email to Sarah McCabe at email@example.com
Pharnext is an advanced clinical stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext focuses on neurodegenerative diseases and has two lead products in clinical development: PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™ . The company identifies and develops synergic combinations of repositioned drugs at low dose. These PLEODRUG™ offer several key advantages: efficacy, safety, and intellectual property including several composition of matter patents already granted. The Company is supported by a world-class scientific team.
The company Pharnext is listed on Euronext Alternext Stock Exchange in Paris (ISIN code: FR00111911287).
For more information, visit www.pharnext.com
Pierre Schwich, +33 (0)1 41 09 22 30
Chief Financial Officer
Investors Relations (Europe)
Anne Hennecke, +49 211 529252 22
MC Services AG
Investors Relations (U.S.)
Stern Investor Relations, Inc.
Sarah McCabe, +1 212-362-1200
Media Relations (Europe)
+33 (0)1 44 54 36 64
Media Relations (U.S.)
Tony Russo, Ph.D., +1 212-845-4251
Victoria Meissner, M.D., +1 646-942-5627
Financial Communication (France)
Julie Coulot, +33 (0)1 44 71 20 40
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
DIMENSION-DATA16.11.2018 09:02 | pressemeddelelse
Dimension Data Global Delivery Centre (GDC) in Prague wins the ABSL 2018 Diamond Award for Business Innovation
DC-LEOSAT16.11.2018 07:02 | pressemeddelelse
FCC Grants LeoSat U.S. Market Access
CO-MPEG-LA16.11.2018 06:03 | pressemeddelelse
German Court Rules Huawei, ZTE Products Infringe AVC Patents
NY-INTERNATIONAL-FLAVORS15.11.2018 22:17 | pressemeddelelse
IFF-LMR Naturals Leads Industry with 90 Certified Vegan Natural Extracts
NV-RIMINI-STREET15.11.2018 21:02 | pressemeddelelse
Rimini Street Expands Investment and Operations in Asia-Pacific
SARTORIUS-STEDIM-BIOTECH15.11.2018 19:17 | pressemeddelelse
Sartorius Stedim Biotech and Lonza Modify Relationship for Supply of Cell Culture Media
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum